Literature DB >> 8256556

Possible association of HTLV-I infection and dementia.

J Lycke1, B Svennerholm, A Svenningsson, P Horal, E Nordqvist-Brandt, O Andersen.   

Abstract

We report a Swedish patient with progressive dementia possibly associated with human T cell-lymphotropic virus type I (HTLV-I) infection. The clinical investigation revealed no typical sings of other neurological disorders. The patient was probably infected in East-Asia 35 years before onset of the disease. High titers of specific HTLV-I antibodies were detectable with solid-phase peptide ELISA in serum (1:1.600) and cerebrospinal fluid (CSF) (1:20), and the CSF/serum anti-HTLV-I antibody ratio indicated intrathecal HTLV-I antibody synthesis. Western blot for HTLV-I and polymerase chain reaction with primers selected for the HTLV-I pol gene were positive in both peripheral blood and cerebrospinal fluid. HTLV-I antigen was also demonstrated after in vitro co-cultivation of mononuclear cells from peripheral blood. Thus, our findings indicate that HTLV-I infection also may be associated with dementia. In addition, this case report calls attention upon HTLV-I as a possible etiologic agent to neurological diseases in countries previously spared from the infection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8256556     DOI: 10.1111/j.1600-0404.1993.tb04216.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  2 in total

1.  Neuropsychological assessment in HTLV-1 infection: a comparative study among TSP/HAM, asymptomatic carriers, and healthy controls.

Authors:  M T T Silva; P Mattos; A Alfano; A Q-C Araújo
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-08       Impact factor: 10.154

2.  Decoding the Role of Astrocytes in the Entorhinal Cortex in Alzheimer's Disease Using High-Dimensional Single-Nucleus RNA Sequencing Data and Next-Generation Knowledge Discovery Methodologies: Focus on Drugs and Natural Product Remedies for Dementia.

Authors:  Peter Natesan Pushparaj; Gauthaman Kalamegam; Khalid Hussain Wali Sait; Mahmood Rasool
Journal:  Front Pharmacol       Date:  2022-02-28       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.